Coherus BioSciences Charts Leaner Path After Earnings Call

Coherus Biosciences ((CHRS)) has held its Q4 earnings call. Read on for the main highlights of the call.

Coherus BioSciences’ latest earnings call struck a notably upbeat tone, as management framed 2025 as a turning point toward a lean, oncology-focused future. Balance sheet repair, rapid LOQTORZI growth, and strong clinical signals anchored the optimism, even as executives acknowledged higher R&D spend, legacy liabilities, and a multi‑year climb to true commercial scale.

Strategic Transformation and Balance Sheet Strengthening

Coherus has effectively reinvented itself as a pure‑play oncology company by divesting its biosimilar franchise for $250 million. The company used the proceeds to slash secured and convertible debt by more than 90%, cutting obligations from roughly $480 million to just $38.8 million by the end of 2025.

Strong LOQTORZI Commercial Momentum

LOQTORZI is emerging as the growth engine, with full‑year 2025 net revenue of $40.8 million versus $19.1 million in 2024, a 113% year‑over‑year jump. In the latest quarter, LOQTORZI generated $12.4 million, up 11% from Q3, supported by a robust 15.5% sequential increase in underlying demand.

Compelling Long-Term Survival Data

Management spotlighted six‑year overall survival data for LOQTORZI plus chemotherapy that show median survival of about 65 months. This compares with under 36 months for chemotherapy alone, implying a roughly 2.5‑year survival advantage that reinforces LOQTORZI’s differentiation and strengthens its standing in treatment guidelines.

Cash and Financing Position

The company ended 2025 with $172.1 million in cash, cash equivalents, and investments, providing a solid base to fund operations. A recent follow‑on equity raise of roughly $50 million adds further flexibility to support commercial build‑out and continued investment in its clinical pipeline.

Reduced Interest Expense and Improved Liquidity

Debt reduction has already translated into meaningful savings, with cash interest paid dropping to $9.9 million in 2025 from $25.4 million in 2024. Coherus also pushed out its earliest debt maturity to May 2029, easing near‑term refinancing risk and improving liquidity visibility.

Operational Efficiency and Cost Discipline

As part of its strategic reset, Coherus has cut headcount by about 35%, from roughly 228 employees to 147. This restructuring helped drive Q4 SG&A from continuing operations down to $23.6 million from $29.6 million a year earlier, about a 20% decline that signals tighter cost control.

Promising Pipeline Data and Near-Term Readouts

On the R&D front, early data for tagmokitug show selective depletion of CCR8‑positive tumor Tregs and increased CD8 T cells, including a partial response in a heavily pretreated head and neck cancer patient. Casdozokitug, in combination with atezolizumab and bevacizumab, posted an objective response rate of 38% and a 17% complete response rate in first‑line liver cancer, with multiple readouts slated from mid‑2026.

Strategic Partnership Validation

A new collaboration with Johnson & Johnson centers on combining tagmokitug with pasritamig, a KLK2‑targeting T‑cell engager, underscoring external confidence in the CCR8 strategy. Management emphasized that such partnerships could position tagmokitug as the Treg depleter of choice and potentially shift future pivotal trial costs to ex‑U.S. partners.

Rising R&D Spend

The pivot to innovation comes with higher investment: R&D expenses from continuing operations climbed to $31.0 million in Q4 2025 from $20.8 million a year earlier, a roughly 49% increase. Management framed this step‑up as necessary to advance multiple oncology programs into and through key clinical inflection points.

Commercial Scale Required to Cover Core Burn

Despite LOQTORZI’s growth, Coherus is still below the scale needed to self‑fund its operations, with full‑year revenue at $40.8 million versus a $175 million peak target by 2028. Management estimates that quarterly revenue must reach about $15–16 million to fully cover commercial costs, and roughly $30–35 million per quarter to offset core cash burn, excluding clinical trial expenses.

Remaining Legacy and Liability Items

Legacy obligations from the prior biosimilar business remain a drag, though they are shrinking. TSA liabilities fell sharply from $254 million to $65 million in Q4, while accrued rebates, fees, and reserves declined from $67 million to $30 million, pointing to ongoing but diminishing cash commitments tied to the transition.

Channel and Revenue Variability

The latest quarter highlighted that reported revenue can lag true prescription demand due to channel dynamics. While LOQTORZI demand grew 15.5% quarter over quarter, net revenue increased only 11% because wholesalers reduced inventory, a pattern investors should watch for as a source of near‑term volatility.

Competitive and Clinical Uncertainties in CCR8 Field

Management also flagged risks in the crowded CCR8 space, where several large players are running substantial programs and single‑agent activity has been limited so far. Coherus expects other studies could be paused or reshaped over time, but acknowledges execution and differentiation risk as its own data mature.

Dependence on Milestones and Future Partner Funding

The funding plan still leans partly on contingent sources, including eligibility for two potential UDENYCA earn‑outs of $37.5 million each based on future sales thresholds. Management is also counting on ex‑U.S. partnership deals to share pivotal development costs, which introduces timing and negotiation uncertainty around certain pipeline investments.

Forward-Looking Guidance and Growth Milestones

Looking ahead, Coherus expects LOQTORZI demand to grow on average 10–15% quarter over quarter and plans to issue full‑year 2026 revenue guidance in August. With over $220 million in cash and recent financing, debt cut by more than 90%, and operating efficiencies in place, management expressed confidence in funding operations into key 2026–2027 data milestones while marching toward a targeted $175 million LOQTORZI run‑rate by 2028.

Coherus’ earnings call painted a picture of a company that has aggressively cleaned up its balance sheet and is now leaning into an oncology‑focused growth story anchored by LOQTORZI and a maturing pipeline. While rising R&D, channel noise, and execution risks remain, investors heard a clear path to scale, improved financial flexibility, and multiple upcoming clinical catalysts.